| Product Code: ETC11626193 | Publication Date: Apr 2025 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 |
The import of colorectal cancer drugs to Norway in 2024 continued to be dominated by key exporters such as the UK, Germany, USA, Denmark, and Metropolitan France. Despite the low concentration levels indicated by the Herfindahl-Hirschman Index (HHI), the market showed steady growth with a Compound Annual Growth Rate (CAGR) of 3.86% from 2020 to 2024. The impressive growth rate of 27.79% from 2023 to 2024 suggests a rising demand for colorectal cancer treatments in Norway, signaling opportunities for pharmaceutical companies in this sector.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Norway Colorectal Cancer Drugs Therapeutic Market Overview |
3.1 Norway Country Macro Economic Indicators |
3.2 Norway Colorectal Cancer Drugs Therapeutic Market Revenues & Volume, 2021 & 2031F |
3.3 Norway Colorectal Cancer Drugs Therapeutic Market - Industry Life Cycle |
3.4 Norway Colorectal Cancer Drugs Therapeutic Market - Porter's Five Forces |
3.5 Norway Colorectal Cancer Drugs Therapeutic Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 Norway Colorectal Cancer Drugs Therapeutic Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.7 Norway Colorectal Cancer Drugs Therapeutic Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Norway Colorectal Cancer Drugs Therapeutic Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing incidence of colorectal cancer in Norway |
4.2.2 Advancements in drug development and targeted therapies |
4.2.3 Growing awareness and screening programs for early detection |
4.3 Market Restraints |
4.3.1 Stringent regulations and approval processes for new drugs |
4.3.2 High treatment costs and reimbursement challenges |
4.3.3 Competition from generic drugs and biosimilars |
5 Norway Colorectal Cancer Drugs Therapeutic Market Trends |
6 Norway Colorectal Cancer Drugs Therapeutic Market, By Types |
6.1 Norway Colorectal Cancer Drugs Therapeutic Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 Norway Colorectal Cancer Drugs Therapeutic Market Revenues & Volume, By Drug Class, 2021 - 2031F |
6.1.3 Norway Colorectal Cancer Drugs Therapeutic Market Revenues & Volume, By Immunotherapy, 2021 - 2031F |
6.1.4 Norway Colorectal Cancer Drugs Therapeutic Market Revenues & Volume, By Chemotherapy, 2021 - 2031F |
6.1.5 Norway Colorectal Cancer Drugs Therapeutic Market Revenues & Volume, By Others, 2021 - 2031F |
6.2 Norway Colorectal Cancer Drugs Therapeutic Market, By Route of Administration |
6.2.1 Overview and Analysis |
6.2.2 Norway Colorectal Cancer Drugs Therapeutic Market Revenues & Volume, By Oral, 2021 - 2031F |
6.2.3 Norway Colorectal Cancer Drugs Therapeutic Market Revenues & Volume, By Intravenous, 2021 - 2031F |
6.2.4 Norway Colorectal Cancer Drugs Therapeutic Market Revenues & Volume, By Intramuscular, 2021 - 2031F |
6.2.5 Norway Colorectal Cancer Drugs Therapeutic Market Revenues & Volume, By Subcutaneous, 2021 - 2031F |
6.2.6 Norway Colorectal Cancer Drugs Therapeutic Market Revenues & Volume, By Others, 2021 - 2031F |
6.3 Norway Colorectal Cancer Drugs Therapeutic Market, By Distribution Channel |
6.3.1 Overview and Analysis |
6.3.2 Norway Colorectal Cancer Drugs Therapeutic Market Revenues & Volume, By Hospital Pharmacies, 2021 - 2031F |
6.3.3 Norway Colorectal Cancer Drugs Therapeutic Market Revenues & Volume, By Retail Pharmacies, 2021 - 2031F |
6.3.4 Norway Colorectal Cancer Drugs Therapeutic Market Revenues & Volume, By Online Pharmacies, 2021 - 2031F |
7 Norway Colorectal Cancer Drugs Therapeutic Market Import-Export Trade Statistics |
7.1 Norway Colorectal Cancer Drugs Therapeutic Market Export to Major Countries |
7.2 Norway Colorectal Cancer Drugs Therapeutic Market Imports from Major Countries |
8 Norway Colorectal Cancer Drugs Therapeutic Market Key Performance Indicators |
8.1 Patient survival rates |
8.2 Adoption rates of new therapeutic drugs |
8.3 Number of clinical trials for colorectal cancer drugs in Norway |
8.4 Patient adherence to prescribed treatment regimens |
8.5 Rate of utilization of targeted therapies in colorectal cancer treatment |
9 Norway Colorectal Cancer Drugs Therapeutic Market - Opportunity Assessment |
9.1 Norway Colorectal Cancer Drugs Therapeutic Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 Norway Colorectal Cancer Drugs Therapeutic Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.3 Norway Colorectal Cancer Drugs Therapeutic Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Norway Colorectal Cancer Drugs Therapeutic Market - Competitive Landscape |
10.1 Norway Colorectal Cancer Drugs Therapeutic Market Revenue Share, By Companies, 2024 |
10.2 Norway Colorectal Cancer Drugs Therapeutic Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |